CJC-1295 No DAC
Modified GRF 1-29
Overview
CJC-1295 No DAC (also called Modified GRF 1-29 or Mod GRF 1-29) is a modified version of the first 29 amino acids of GHRH without the Drug Affinity Complex (DAC) used in standard CJC-1295. Without DAC the peptide has a shorter half-life of 30-60 minutes compared to CJC-1295 DAC's week-long duration. This shorter half-life is often considered advantageous as it produces a more physiological pulsatile GH release pattern rather than the continuous elevation from CJC-1295 with DAC. It is one of the most widely used GHRH analogs in combination with GHRP peptides.
Mechanism of Action
Mod GRF 1-29 binds to GHRH receptors on pituitary somatotrophs stimulating GH synthesis and pulsatile release through the same mechanism as endogenous GHRH. The four amino acid substitutions from native GHRH 1-29 improve stability against enzymatic degradation extending the half-life from the 2 minutes of native GHRH to 30-60 minutes without altering receptor binding affinity. When combined with a GHRP peptide (such as Ipamorelin or GHRP-2) the two compounds work synergistically — GHRH analogs increase the amount of GH released per pulse while GHRPs increase the frequency and amplitude of pulses producing GH release significantly greater than either compound alone.
Dosage Information
Typical Dose
100 mcg per dose
Frequency
2-3 times daily, typically combined with a GHRP
Administration
Subcutaneous injection
Notes
Almost always stacked with a GHRP (Ipamorelin, GHRP-2, or GHRP-6) for synergistic GH release. Administer on empty stomach and avoid eating for 30-40 minutes post-injection to maximize GH pulse.
Where does CJC-1295 No DAC sit?
See how this peptide compares across all 111 peptides in our database.
Evidence Score
0.58
Potential Side Effects
Community Experiences
No experiences shared yet. Be the first!
Quick Facts
- Administration
- Subcutaneous injection
- Typical Dose
- 100 mcg per dose
- Frequency
- 2-3 times daily, typically combined with a GHRP
- References
- 0 curated + 14 from PubMed
- Clinical Trials
- 13 registered
- Evidence Score
- 0.6 / 100